SCHEDULE: Gilead Sciences' Option to Increase Stake in Arcus Biosciences Expires, Maintaining 29.7% Ownership

Gilead Sciences, Inc.'s option to acquire additional shares in Arcus Biosciences, Inc., potentially increasing its stake to 35%, expired on July 13, 2025, leaving its beneficial ownership at 29.7%.

Summary

• Gilead Sciences, Inc. (the "Reporting Person") currently beneficially owns 31,424,760 shares of Arcus Biosciences, Inc. ("Issuer") Common Stock.
• This ownership represents 29.7% of Arcus Biosciences' outstanding Common Stock, calculated based on 105,885,138 shares issued and outstanding as of May 1, 2025.
• The shares held by Gilead include purchases from a 2020 Public Offering (2,200,000 shares), an initial Purchase Agreement (5,963,029 shares), an Amended and Restated Purchase Agreement (5,650,000 shares), a Second Amended and Restated Purchase Agreement (1,010,000 shares), a Third Amended and Restated Purchase Agreement (15,238,095 shares), and a subsequent Public Offering (1,363,636 shares).
• On July 13, 2025, Gilead Sciences' option to purchase additional shares from Arcus Biosciences, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, expired.
• Jeffrey A. Bluestone, a member of the Issuer's Scientific Advisory Board, beneficially owns 7,156 shares (options exercisable within 60 days), representing 0.01% of the class.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative for Arcus Biosciences as the expiration of Gilead's option removes a potential source of future capital and a deeper equity commitment from a key strategic partner. For Gilead, it's neutral as it removes a potential future obligation.

Negatives

• The expiration of Gilead's option to purchase additional shares means Arcus Biosciences will not receive further capital from Gilead through this specific mechanism, potentially requiring Arcus to seek alternative funding sources for future growth or operations.

Risks

• Arcus Biosciences may face increased capital raising needs from other sources if it had factored the potential exercise of Gilead's option into its long-term financial planning.
• The expiration of the option could be perceived by the market as a lack of further commitment or reduced strategic interest from Gilead, potentially impacting investor sentiment towards Arcus Biosciences.

Future Outlook

The expiration of Gilead's option to increase its stake in Arcus Biosciences indicates that Gilead will not be increasing its ownership percentage through this specific mechanism in the near future. This may necessitate Arcus Biosciences to explore other avenues for capital infusion if additional funding is required for its operations or strategic initiatives.

Industry Context

This filing reflects a specific investment relationship within the biotechnology and pharmaceutical sectors. While Gilead Sciences remains a significant strategic partner and investor in Arcus Biosciences, the expiration of the option to increase its stake suggests a stabilization of the current ownership structure rather than an ongoing expansion of Gilead's direct equity control. This is a common dynamic in strategic alliances where initial investment phases are followed by periods of operational collaboration.

Comparison to Industry Standards

• Gilead's 29.7% stake in Arcus Biosciences represents a substantial minority interest, typical of strategic partnerships in the biotech industry where a larger pharmaceutical company invests in a smaller, innovative biotech firm to gain access to pipeline assets or technology without full acquisition.
• The structure of initial equity purchases combined with an option for further investment is a standard mechanism for establishing and potentially deepening such alliances, providing flexibility for both parties based on clinical progress and market conditions.
• The expiration of the option, while not necessarily negative, means Arcus Biosciences will not benefit from the potential capital infusion that exercising such an option would provide, a factor that other biotech companies with similar strategic partners might still have as a future funding avenue.

Related Party Transactions

• The document details Gilead Sciences' historical purchases of Arcus Biosciences' Common Stock, which are related party transactions given Gilead's significant ownership stake and strategic partnership.

Stakeholder Impact

• Shareholders of Arcus Biosciences may view the expiration of Gilead's option as a missed opportunity for further investment from a strategic partner, potentially impacting their perception of future funding and partnership strength.
• Employees of Arcus Biosciences might perceive this as a signal regarding the long-term financial commitment from Gilead, though the existing partnership remains intact.

Key Dates

Recommendation

Keywords

Gilead Sciences, Arcus Biosciences, Schedule 13D, beneficial ownership, equity stake, option expiration, common stock, biotechnology, pharmaceuticals, investment, strategic partnership